These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
27. The role of hypomethylating agents in myelodysplastic syndrome: changing the management paradigm. Merkel DG; Nagler A Expert Rev Hematol; 2013 Dec; 6(6):665-76. PubMed ID: 24191866 [TBL] [Abstract][Full Text] [Related]
28. 5-azacytidine and decitabine monotherapies of myelodysplastic disorders. Kuykendall JR Ann Pharmacother; 2005 Oct; 39(10):1700-9. PubMed ID: 16144884 [TBL] [Abstract][Full Text] [Related]
29. DNA methylation inhibitors in the treatment of leukemias, myelodysplastic syndromes and hemoglobinopathies: clinical results and possible mechanisms of action. Lübbert M Curr Top Microbiol Immunol; 2000; 249():135-64. PubMed ID: 10802943 [No Abstract] [Full Text] [Related]
30. [5-day decitabine for treatment of myelodysplastic syndromes with complex karyotype abnormalities and acute myeloid leukemia]. Gao S; Hu XH; Qiu HY; Xu Y; Jin ZM; He GS; Tang XW; Han Y; Chen SN; Sun AN; Wu DP Zhonghua Xue Ye Xue Za Zhi; 2013 Jun; 34(6):542-3. PubMed ID: 23827117 [No Abstract] [Full Text] [Related]
31. Clinical update on hypomethylating agents. Duchmann M; Itzykson R Int J Hematol; 2019 Aug; 110(2):161-169. PubMed ID: 31020568 [TBL] [Abstract][Full Text] [Related]
32. Targeting epigenetic pathways in acute myeloid leukemia and myelodysplastic syndrome: a systematic review of hypomethylating agents trials. Yun S; Vincelette ND; Abraham I; Robertson KD; Fernandez-Zapico ME; Patnaik MM Clin Epigenetics; 2016; 8():68. PubMed ID: 27307795 [TBL] [Abstract][Full Text] [Related]
33. [Demethylating medication in myelodysplastic syndrome]. Manson ML; Derissen EJ; Wijermans PW; Schellens JH; Beijnen JH Ned Tijdschr Geneeskd; 2012; 156(4):A3167. PubMed ID: 22278034 [TBL] [Abstract][Full Text] [Related]
34. Optimizing the use of hypomethylating agents in myelodysplastic syndromes: Selecting the candidate, predicting the response, and enhancing the activity. Madanat Y; Sekeres MA Semin Hematol; 2017 Jul; 54(3):147-153. PubMed ID: 28958288 [TBL] [Abstract][Full Text] [Related]
35. Therapy with azanucleosides for myelodysplastic syndromes. Quintás-Cardama A; Santos FP; Garcia-Manero G Nat Rev Clin Oncol; 2010 Aug; 7(8):433-44. PubMed ID: 20551943 [TBL] [Abstract][Full Text] [Related]
36. Update of the decitabine experience in higher risk myelodysplastic syndrome and analysis of prognostic factors associated with outcome. Kantarjian HM; O'Brien S; Shan J; Aribi A; Garcia-Manero G; Jabbour E; Ravandi F; Cortes J; Davisson J; Issa JP Cancer; 2007 Jan; 109(2):265-73. PubMed ID: 17133405 [TBL] [Abstract][Full Text] [Related]